Immunoglobulin News and Research

RSS

Powerful neutralizing antibody against SARS-CoV-2 variants of concern

A new paper discusses a new antibody with potent neutralizing activity against the ancestral SARS-CoV-2 strain, as well as newer variants of SARS-CoV-2.

10 Oct 2021

Oral and intranasal COVID-19 vaccines show promising results in hamster model

A new preprint discusses the protective effect of an oral adenovirus-vectored vaccine based on the SARS-CoV-2 spike against viral transmission and disease in hamsters.

8 Oct 2021

BNT162b2 COVID vaccine humoral response substantially reduced after 6 months

The rollout of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is expanding worldwide. However, little is known about the duration of protection offered by these vaccines. Real-world data on the kinetics of antibodies are beginning to appear, but a holistic picture of immunity duration is still not available.

7 Oct 2021

Graphene biosensor in a portable and wireless device for rapid SARS-CoV-2 detection

A new study posted to the medRxiv* server and led by Dr. Mattia D'Agostino, Dr. Eleonora Pavoni and Dr. Alice Romagnoli from the Polytechnic University of Marche in Ancona (Italy), a gFET biosensor that uses angiotensin-converting enzyme 2 (ACE2) as a bioreceptor has been put forth as a viable solution.

6 Oct 2021

Durability of immunity to SARS-CoV-2 reinfection

The current study used data on the durability of immunity among evolutionarily close coronavirus relatives of SARS-CoV-2 to estimate times to reinfection.

6 Oct 2021

Study shows strong protective effect of IgG3 antibodies in SARS-CoV-2 infection

Researchers published a study on the expression and functional analyses of a neutralizing mAb with identical variable domains but different constant HCs, representing IgG1-4.

6 Oct 2021

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Your saliva may be able to tell you if you’ve developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, suggests a new medRxiv* preprint study. In immunocompromised groups, salivary Immunoglobulin G (IgG) antibody levels were associated with IgG titers in blood serum 3 to 4 weeks after mRNA vaccination.

5 Oct 2021

Study looks at immunosuppressants and COVID vaccine efficacy

Researchers investigate the effects of five established immunosuppressant medications following COVID-19 vaccination.

4 Oct 2021

How durable is the immune response generated from the BNT162b2 vaccine?

In a recent study, researchers analyzed antibody responses to the homologous Wu strain and several other SARS-CoV-2 variants after BNT162b2 vaccination.

4 Oct 2021

Using a new public antibody to understand SARS-CoV-2 neutralization

SARS-CoV-2 infects host cells by binding to the angiotensin convertase 2 receptor (ACE2) on the cell surface through its trimeric spike (S) protein. SARS-CoV enters host human cells through endosomes, while SARS-CoV-2 enters through the cell surface and endosomes. The present study published in the journal “Cell Reports” aimed to understand the mechanisms of SARS-CoV-2 antibody neutralization to facilitate the development of therapeutic interventions for COVID-19.

4 Oct 2021

Dual therapy improves cardiac outcomes in pediatric patients suffering from MIS-C

A recent study by a multidisciplinary team of cardiologists and infectious disease specialists at Children's Hospital Colorado (Children's Colorado) found that pediatric patients suffering from Multisystem Inflammatory Syndrome (MIS-C) who received initial, intensified therapy consisting of intravenous immunoglobulin (IVIG) plus Infliximab had improved cardiac outcomes versus those who received IVIG alone.

30 Sep 2021

Effect of biologic therapy on COVID-19 in children suffering from rheumatic diseases

A new study aimed to determine the course of SARS-CoV-2 infection in children suffering from rheumatic disease and were receiving bDMARD treatment.

29 Sep 2021

Vaccine-induced SARS-CoV2 immune responses decline at similar rates as those after infection, study finds

A new preprint describes the causal role of waning antibody titers in decreased antibody persistence at one year.

29 Sep 2021

Quantification of antibody titers against SARS-CoV-2 variants elicited by BNT162b2 vaccine

A new study discusses the development of dedicated reagents against the SARS-CoV-2 spike protein through the use of an automated CLEIA system.

28 Sep 2021

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

A new study discusses the utility of a third booster dose in patients with myelofibrosis.

27 Sep 2021

Chronic COVID-19 and divergent variants of SARS-CoV-2

A new study discusses the isolation of two variants of concern (VOCs) from an immunocompromised COVID-19 patient.

27 Sep 2021

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

New research discusses the development of soluble prefusion-stabilized spike trimers (CoV2 preS dTM) comprising adjuvant AS03.

27 Sep 2021

Characterization of SARS-CoV-2 infections diagnosed after mRNA BNT162b2 vaccination

A team from the National Institute for Infectious Diseases “L. Spallanzani” (INMI) has recently reported their study on 94 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections (47.9% symptomatic, 52.1% asymptomatic) that occurred after the first or second vaccine dose against SARS-CoV-2 in the Lazio region (Central Italy).

27 Sep 2021

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

Despite the advent of numerous vaccines and the discovery of passive monoclonal antibodies for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), there remains an urgent need for definitive therapies for coronavirus disease-2019 (COVID-19) patients.

27 Sep 2021

Effect of prior SARS-CoV-2 infection on post-vaccination SARS-CoV-2 spike IgG antibodies

Natural infection or vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confer considerable protection against reinfection and reduce the risk of severe Coronavirus disease 2019 (COVID-19) outcomes.

24 Sep 2021

Immunoglobulin News and Research

Powerful neutralizing antibody against SARS-CoV-2 variants of concern

Oral and intranasal COVID-19 vaccines show promising results in hamster model

BNT162b2 COVID vaccine humoral response substantially reduced after 6 months

Graphene biosensor in a portable and wireless device for rapid SARS-CoV-2 detection

Durability of immunity to SARS-CoV-2 reinfection

Study shows strong protective effect of IgG3 antibodies in SARS-CoV-2 infection

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Study looks at immunosuppressants and COVID vaccine efficacy

How durable is the immune response generated from the BNT162b2 vaccine?

Using a new public antibody to understand SARS-CoV-2 neutralization

Dual therapy improves cardiac outcomes in pediatric patients suffering from MIS-C

Effect of biologic therapy on COVID-19 in children suffering from rheumatic diseases

Vaccine-induced SARS-CoV2 immune responses decline at similar rates as those after infection, study finds

Quantification of antibody titers against SARS-CoV-2 variants elicited by BNT162b2 vaccine

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

Chronic COVID-19 and divergent variants of SARS-CoV-2

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

Characterization of SARS-CoV-2 infections diagnosed after mRNA BNT162b2 vaccination

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

Effect of prior SARS-CoV-2 infection on post-vaccination SARS-CoV-2 spike IgG antibodies

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News